Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Sanofi has unveiled plans to invest “at least” $20bn into the US by 2030, with the commitment including a significant ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

AB Science SA (Euronext - FR0010557264 - AB) today reports its revenues for the year 2024 and provides an update on its activities. CLINICAL DEVELOPMENT KEY EVENTS DURING THE YEAR 2024 AND SINCE ...

Assistant in the Theory and Practice of Physic, Harvard University; Assistant in Clinical Pathology, the Boston City Hospital. (From the Laboratory of the Department of the Theory and Practice of ...

PRLs in Tolebrutinib Trials At ACTRIMS, Oh presented a post hoc analysis of PRLs in the phase III trials of the investigational Bruton's tyrosine kinase (BTK) inhibitor tolebrutinib. "We're very ...

and Sanofi's experimental tolebrutinib. "The FDA appears to be focused on confirmed disability worsening endpoints where vidofludimus compares well in the PPMS population," the analysts wrote.

While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis (SPMS) in the Netherlands, it did not significantly ...

A new machine learning tool, a form of artificial intelligence (AI), may accurately detect the transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial ...

New Delhi: Torrent Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase III clinical ...

Suggested remit: To appraise the clinical and cost effectiveness of tolebrutinib within its marketing authorisation for treating non-relapsing secondary progressive multiple sclerosis.